Divergent product biology emerged: high-dose responses tracked with naïve/central-memory enrichment, whereas low-dose ...

EBV seroconversion confers markedly increased MS risk in large longitudinal military cohorts, supporting EBV as necessary but ...

High-frequency, low-dose rituximab achieved ~85% peripheral CLL clearance within 1 hour and ~34% nodal reduction in 1 week, with macrophage phagocytosis and complement as dominant mechanisms.

Right-sided performance improved most, with adenoma detection rising from 18.0% to 31.8%, addressing a common vulnerability of standard colonoscopy quality and missed proximal lesions.

Six peptides received narrow advisory support for potential 503A Bulks List inclusion, an atypical outcome given FDA staff recommendations against all seven under review. Legal compounding remains ...